Findings

What do systematic reviews say?

80 questions · 82 findings · 13 reviews · Epilepsy · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 9.8%GRADE not reported 0 · 0%Very low 3 · 3.7%Low 29 · 35.4%Moderate 31 · 37.8%High 11 · 13.4%

Sodium valproate vs phenytoin monotherapy

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures

Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (low certainty).

1 finding from 1 review

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.94 [0.55, 1.61]
5 studies · 341 participants
Low

Sodium valproate vs phenytoin monotherapy

Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures

Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).

1 finding from 1 review

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.97 [0.72, 1.3]
5 studies · 395 participants
Low

Sodium valproate vs phenytoin monotherapy

Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures

Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).

1 finding from 1 review

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.96 [0.71, 1.29]
4 studies · 270 participants
Moderate

Intervention not reported

Time to first seizure ‐ stratified by epilepsy type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures

The intervention showed no clear difference in time to first seizure ‐ stratified by epilepsy type ‐ Generalised… (moderate certainty).

1 finding from 1 review

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures 2013 · Cochrane Headline outcomes only
HR 1.14 [0.73, 1.78]
3 studies · 131 participants
Moderate

Intervention not reported

Time to treatment withdrawal ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures

The intervention may leads to higher time to treatment withdrawal ‐ stratified by seizure type ‐… (low certainty).

1 finding from 1 review

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures 2013 · Cochrane Headline outcomes only
HR 4.04 [1.61, 10.14]
2 studies · 95 participants
Low

Intervention not reported

Time to 12‐month remission ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures

The intervention showed no clear difference in time to 12‐month remission ‐ stratified by seizure type ‐… (moderate certainty).

1 finding from 1 review

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures 2013 · Cochrane Headline outcomes only
HR 0.77 [0.46, 1.28]
3 studies · 131 participants
Moderate

Intervention not reported

Time to 6‐month remission ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures

The intervention showed no clear difference in time to 6‐month remission ‐ stratified by seizure type ‐ Generalised… (moderate certainty).

1 finding from 1 review

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures 2013 · Cochrane Headline outcomes only
HR 0.79 [0.51, 1.24]
3 studies · 131 participants
Moderate

Carbamazepine vs phenytoin

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy

Carbamazepine may leads to higher time to treatment failure (any reason related to treatment)… compared with phenytoin (time to treatment failure) (low certainty).

1 finding from 1 review

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 2.38 [1.04, 5.47]
2 studies · 118 participants
Low

Carbamazepine vs phenytoin

Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy

Carbamazepine showed no clear difference in time to first seizure after randomisationSubgroup: generalisedonset… compared with phenytoin (secondary outcomes) (low certainty).

1 finding from 1 review

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 1.19 [0.81, 1.75]
3 studies · 150 participants
Low

Carbamazepine vs phenytoin

Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy

Carbamazepine showed no clear difference in time to achieve 12‐month remissionSubgroup: generalisedonset tonic… compared with phenytoin (secondary outcomes) (low certainty).

1 finding from 1 review

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 0.88 [0.58, 1.33]
2 studies · 121 participants
Low

Topiramate vs carbamazepine

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy

Topiramate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with carbamazepine (low certainty).

1 finding from 1 review

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 0.88 [0.56, 1.39]
2 studies · 192 participants
Low

Topiramate vs carbamazepine

Time to first seizure after randomisation Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy

Topiramate showed no clear difference in time to first seizure after randomisation Subgroup: generalised… compared with carbamazepine (moderate certainty).

1 finding from 1 review

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 1.08 [0.7, 1.66]
2 studies · 190 participants
Moderate

Topiramate vs carbamazepine

Time to 12‐month remission of seizures Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy

Topiramate showed no clear difference in time to 12‐month remission of seizures Subgroup: generalised onset… compared with carbamazepine (moderate certainty).

1 finding from 1 review

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review 2019 · Cochrane Headline outcomes only
HR 0.92 [0.61, 1.41]
2 studies · 190 participants
Moderate

Lamotrigine vs carbamazepine

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure…

Summary of findings: lamotrigine may leads to lower time to treatment failure (any reason related to treatment)… compared with carbamazepine (low certainty).

1 finding from 1 review

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.51 [0.33, 0.78]
6 studies · 299 participants
Low

Lamotrigine vs carbamazepine

Time to first seizure ‐ generalised epilepsy Range of · adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure…

Summary of findings: lamotrigine showed no clear difference in time to first seizure Subgroup: generalised onset seizures Range of compared with carbamazepine (low certainty).

1 finding from 1 review

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.98 [0.65, 1.48]
6 studies · 277 participants
Low

Carbamazepine vs phenobarbitone

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy

Carbamazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenobarbitone (low certainty).

1 finding from 1 review

Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.65 [0.35, 1.23]
3 studies · 156 participants
Low

Carbamazepine vs phenobarbitone

Carbamazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenobarbitone (low certainty).

1 finding from 1 review

Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.8 [0.55, 1.15]
5 studies · 238 participants
Low

Carbamazepine vs phenobarbitone

Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy

Carbamazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenobarbitone (low certainty).

1 finding from 1 review

Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 1.56 [0.99, 2.44]
3 studies · 158 participants
Low

Sulthiame vs levetiracetam

Adverse effects (general symptoms) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.08 [0.76, 1.54]
1 study · 43 participants
Low

Clobazam vs placebo

50% reduction in generalised‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found